medigraphic.com

2023, Number 4

<< Back Next >>

Rev Hematol Mex 2023; 24 (4)

Frequency and clinical association of NY-ESO-1 gene expression in diffuse large B-cell lymphoma

Olarte CI, Ramos PC, Miranda PE, Gallardo RAG, Garrido GE, Collazo JJ, Martínez TA

Language: English
References: 35
Page: 188-194
PDF size: 265.54 Kb.


ABSTRACT

Objectives: To evaluate the frequency of expression and determine the expression levels of the NY-ESO-1 gene in patients with diffuse large B-cell lymphoma, as well as to examine its relationship with clinical parameters and survival.
Materials and Methods: Prospective, observational and experimental clinical study was done analyzing NY-ESO-1 gene expression levels using real-time quantitative RT-PCR (qRT-PCR) in patients with diffuse large B-cell lymphoma. The associations between the expression of the NY-ESO-1 gene and the clinical variables were evaluated using the χ2 test and Fisher’s exact test. Overall survival (OS) was determined using the Kaplan-Meier method.
Results: There were included 112 patients. The results showed that the NY-ESO-1 gene was expressed in 46.4% (52/112) of patients with diffuse large B-cell lymphoma, and NY-ESO-1 gene expression was associated with clinical parameters such as LDH, clinical stage, international prognostic index (p ≤ 0.05). High levels of NY-ESO-1 gene expression were correlated with advanced disease stages, and the survival rates after 5.3 years of tracking were lower in the patients expressing the NY-ESO-1 gene (66.4%) than in those not expressing the gene (23.1%).
Conclusions: The expression levels of the NY-ESO-1 gene in patients with diffuse large B-cell lymphoma may be of great utility for diagnosing and determining the prognosis of this disease.


REFERENCES

  1. Castellanos H, Ramos C, Murillo C, Montaño E, et al. Quimioterapiaen linfoma no Hodgkin: 17 años de experienciaen el Hospital General de México. Rev Med Hosp Gen Mex 2010; 73 (4): 213-218.

  2. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, JaffeES. The 2008 WHO classification of lymphoid neoplasmsand beyond: evolving concepts and practical applications.Blood 2011; 117 (19): 5019-32. doi: 10.1182/blood-2011-01-293050.

  3. Hartmann EM, Ott G, Rosenwald A. Molecular biology andgenetics of lymphomas. Hematol Oncol Clin North Am2008; 22 (5): 807-823. doi: 10.1016/j.hoc.2008.07.004.

  4. Harris NL, Stein H, Coupland SE, Hummel M, et al. Newapproaches to lymphoma diagnosis. Hematology AmSoc Hematol Educ Program 2001; 194-220. doi: 10.1182/asheducation-2001.1.194.

  5. Brenner H, Gondos A, Pulte D. Ongoing improvement inlong-term survival of patients with Hodgkin disease at allages and recent catch-up of older patients. Blood 2008;111 (6): 2977-2983. doi: 10.1182/blood-2007-10-115493.

  6. Grah JJ, Katalinic D, Juretic A, Santek F, et al. Clinical significanceof immunohistochemical expression of cancer/testistumor-associated antigens (MAGE-A1, MAGE-A3/4, NYESO-1) in patients with non-small cell lung cancer. Tumori2004; 100 (1): 60-8. doi: 10.1700/1430.15817.

  7. Coiffier B, Lepage E, Briere J, Herbrecht R, et al. CHOP chemotherapyplus rituximab compared with CHOP alone inelderly patients with diffuse large B-cell lymphoma. N EnglJ Med 2002; 346 (4): 235-42. doi: 10.1056/NEJMoa011795.

  8. Hofmann M, Ruschenburg I. mRNA detection of tumorrejectiongenes BAGE, GAGE, and MAGE in peritonealfluid from patients with ovarian carcinoma as a potentialdiagnostic tool. Cancer 2002; 96 (3): 187-93. doi: 10.1002/cncr.10622.

  9. Coombes RC, Caballero OL, Shousha S, Ghaem-MaghamiS, et al. NY-ESO-1 expression in DCIS: A new predictor ofgood prognosis. Oncoscience 2017; 4 (3-4): 33-40. doi:

  10. 10.18632/oncoscience.348.10. Gnjatic S, Nishikawa H, Jungbluth AA, Güre A, et al. NY- ESO-1: review of a immunogenic tumor antigen. Adv CancerRes 2006; 95: 1-30. doi: 10.1016/S0065-230X(06)95001-5.

  11. Ueda S, Miyahara Y, Nagata Y, Sato E, et al. NY-ESO-1 antigenexpression and immune response are associatedwith poor prognosis in MAGE-A4-vaccinated patientswith esophageal or head/neck squamous cell carcinoma.Oncotarget 2018; 9 (89): 35997-36011. doi: 10.18632/oncotarget.26323.

  12. Iura K, Kohashi K, Hotokebuchi Y, Ishii T, et al. Cancer-testisantigens PRAME and NY-ESO-1 correlate with tumour gradeand poor prognosis in myxoid liposarcoma. J Pathol Clin Res2015; 1 (3): 144-59. doi: 10.1002/cjp2.16.

  13. Park TS, Groh EM, Patel K, Kerkar S, et al. Expressionof MAGE-A and NY-ESO-1 in primary and metastaticcancers. J Immunother 2016; 39 (1): 1-7. doi: 10.1097/CJI.0000000000000101.

  14. Krüger S, Ola V, Feller AC, Fischer D, Friedrich M. Expressionof cancer-testis antigen CT7 (MAGE-C1) in breast cancer: animmunohistochemical study with emphasis on prognosticutility. Pathol Oncol Res 2007; 13 (2): 91-6. doi: 10.1007/BF02893483.

  15. Andrade VC, Vettore AL, Felix RS, Almeida M, et al.Prognostic impact of cancer/testis antigen expressionin advanced stage multiple myeloma patients. CancerImmunol 2008; 82.

  16. Andrade VC, Vettore AL, Regis MR, Felix R, et al. Frequencyand prognostic relevance of cancer testis antigen 45expression in multiple myeloma. Exp Hematol 2009; 37(4):446-9. doi: 10.1016/j.exphem.2008.12.003.

  17. John T, Starmans MH, Chen YT, Russell P, et al. The role ofcancer-testis antigens as predictive and prognostic markersin non-small cell lung cancer. PLoS One 2013; 8 (7). doi:10.1371/journal.pone.0067876.

  18. Cerón-Maldonado R, Martínez-Tovar A, Ramos-PeñafielCO, Miranda-Peralta E, et al. Detection and analysis oftumour biomarkers to strengthen the diagnosis of acuteand chronic leukaemias. Rev Med Hosp Gen Mex 2015; 78(2): 78-84. DOI: 10.1016/j.hgmx.2015.04.006.

  19. Larouche J, Berger F, Chassagne-Clement C, Ffrencg M, etal. Lymphoma recurrence 5 years or more following diffuselarge B-cell lymphoma: Clinical characteristics and outcome.J Clin Oncol 2009; 27 (15 suppl): 8562. doi: 10.1200/JCO.2009.24.5860.

  20. Alonso-Alvarez S, Redondo-Guijo A, Blanco Ó, Alcoceba M,et al. Lymphoma heterogeneity: three different histologicalpictures and one unique clone. Case Rep Hematol 2016;2016: 3947510. doi: 10.1155/2016/3947510.

  21. Lee HJ, Kim JY, Song IH, Park IA, Yu JH, Gong G. Expressionof NY-ESO-1 in triple-negative breast cancer isassociated with tumor-infiltrating lymphocytes and agood prognosis. Oncology 2015; 89 (6): 337-44. doi:10.1159/000439535.

  22. Küçükzeybek BB, Bener S, Çallı AO, Paksoy TD, PayzinB.Prognostic significance of Bcl-2 and p53 protein expressionsand Ki67 proliferative index in diffuse large B-celllymphoma. Turk J Haematol 2013; 30 (3): 275-82. doi:10.4274/Tjh.2011.0034.

  23. Bujas T, Marusic Z, PericBalja M, Mijic A, Kruslin B, Tomas D.MAGE-A 3/4 and NY-ESO-1 antigens expression in metastaticesophageal squamous cell carcinoma. Eur J Histochem2011; 55 (1): 30-46. doi: 10.4081/ejh.2011.e7.

  24. Endo M, Graaff M, IngramDM, Lim S, et al. NY-ESO-1(CTAG1B) expression in mesenchymal tumors. Mod Pathol2015; 28 (4): 587-95. doi: 10.1038/modpathol.2014.155.

  25. Hudolin T, KastelanZ, Ilic I, Levarda-Hudolin K. Immunohistochemicalanalysis of the expression of MAGE-A andNY-ESO1 cancer/testi antigens in diffuse large cell testicularlymphoma. J Transl Med 2013; 5 (16): 11-123. doi:10.1186/1479-5876-11-123.

  26. Grupp K, Ospina-Klinck D, Tsourlakis MC, Koop C, et al. NYESO-1 expression is tightly linked to TMPRSS2-ERG fusionin prostate cancer. Prostate 2014; 74 (10): 1012-22. doi:10.1002/pros.22816.

  27. Nakada T, Noguchi Y, Satoh S, Ono T, et al. NY-ESO1 mRNAexpression and immunogenicity in advanced prostatecancer. Cancer Immun 2003; 31: 3-10.

  28. Kurashige T, Noguchi Y, Saika T, Ono T, et al. NY-ESO1 expressionand immunogenicity associated with transitionalcell carcinoma: correlation with tumor grade. Cancer Res2001; 61 (12): 4671-4.

  29. Olarte I, Martinez A, Ramos-Peñafiel C, Castellanos H, etal. MAGE-A3 expression is an adverse prognostic factorin diffuse large B-cell lymphoma. Hematology 2011; 16(6): 368-72. doi: 10.1179/102453311X13085644680384.

  30. Mendoza-Salas I, Olarte-Carrillo E, Miranda-Peralta C,Ramos-Peñafiel C, et al. Frequency of cancer testis antigensin chronic myeloid leukemia. Rev Med Hosp Gen Mex 2016;79 (2): 46-5. DOI: 10.1016/j.hgmx.2015.10.003.

  31. Gure AO, Chua R, Williamson B, Gonen M, et al. Cancertestisgenes are coordinately expressed and are markers ofpoor outcome in non-small cell lung cancer. Clin Cancer Res2005; 11 (22): 8055-806. https://doi.org/10.1158/1078-0432.ccr-05-1203.

  32. Perez D, Hauswirth F, Jager D, Mtezger U, et al. Protein expressionof cancer testis antigens predicts tumor recurrenceand treatment response to imatinib in gastrointestinalstromal tumors. Int J Cancer 2011; 128 (12): 2947-295.doi: 10.1002/ijc.25836.

  33. Shustik J, Han G, Farinha P, Johnson N, et al. Correlationsbetween BCL6 rearrangement and outcome in patientswith diffuse large B-cell lymphoma treated with CHOP orR-CHOP. Haematologica 2010; 95 (1): 96-101. doi: 10.3324/haematol.2009.007203.

  34. Monte M, Simonatto M, Peche LY, et al. MAGE-A tumorantigens target p53 transactivation function throughhistone deacetylase recruitment and confer resistance tochemotherapeutic agents. Proc Natl Acad Sci USA 2006;103 (30): 11160-5. doi: 10.1073/pnas.0510834103.

  35. Kawano R, Karube K, Kikuchi M, Takeshita M, et al. Oncogeneassociated cDNA microarray analysis shows PRAME gene expressionis a marker for response to anthracycline containingchemotherapy in patients with diffuse large B-cell lymphoma.J Clin Exp Hematop 2009; 49 (1): 1-7. doi: 10.3960/jslrt.49.1.




2020     |     www.medigraphic.com